AnaptysBio Inc at Barclays Global Healthcare Conference Transcript
Hello again everyone, Etzer Darout, Senior Biotech Analyst at Barclays, my pleasure to have AnaptysBio CEO, Dan Faga, with us this morning. And maybe just to kick us off, Dan, if you could just give us an overview on AnaptysBio for those less familiar with the story. Perfect.
We're in exciting times right now. We're approximately a month or two months out from creating a second company called, First Tracks Bio, which will be the biopharma operations from Anaptys that we're spinning off. Anaptys has been around for over 20 years developing antibodies.
We have two successful programs so far out of our platform. One Jemperli, dostarlimab, which is being sold by GSK, it's oncology drug PD-1 antagonist, and the second has a PDUFA date at the end of the year, it's called imsidolimab for GPPs, which hopefully will be sold at the end of this year by a company called Vanda.
Those two programs will stay behind, forming a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
